Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

12 Nov 2017

• By Sten Stovall

Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.

Retina — Novartis' Brolucizumab Shows Further Advantages In nAMD Trials Versus Aflibercept • Source: Shutterstock

Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

More from Sensory

More from Therapy Areas